Equities

Allergy Therapeutics PLC

AGY:LSE

Allergy Therapeutics PLC

Health CarePharmaceuticals and Biotechnology
  • Price (GBX)10.90
  • Today's Change-1.00 / -8.40%
  • Shares traded512.78k
  • 1 Year change72.47%
  • Beta1.4518
Data delayed at least 20 minutes, as of Feb 06 2026 16:35 GMT.
More ▼

Profile data is unavailable for this security.

About the company

Allergy Therapeutics plc is a United Kingdom-based international commercial biotechnology company. The Company is focused on the treatment and diagnosis of allergic disorders, including aluminum free immunotherapies that have the potential to cure disease. It sells proprietary and third-party products from its subsidiaries in nine European countries and via distribution agreements in an additional 10 countries. It sells both injectable and sublingual (oral) allergen-specific immunotherapies. Its pipeline of products in clinical development includes vaccines for grass, tree, house dust mite and peanut. Its therapies are traded under various brand names depending on the market, such as Pollinex Quattro, Polligoid and TA Graser Top. Its commercial products include Pollinex Quattro, Oralvac, Venomil, Venom ATL Polistes Dominula, Synbiotics and Acarovac Plus. Its pipeline candidates include Grass MATA MPL, Birch MATA MPL, Ragweed MATA MPL, Trees MATA MPL, and VLP Peanut.

  • Revenue in GBP (TTM)55.04m
  • Net income in GBP-40.13m
  • Incorporated2004
  • Employees584.00
More ▼

Peer analysis

CompanyRevenue (TTM)Net income (TTM)Market capEmployeesMarket Cap /
Employees
Shanghai Haixin Group Co Ltd83.96m16.65m710.63m715.00710.63m715.00
Procter & Gamble Health Ltd105.12m25.11m712.40m1.33k712.40m1.33k
Phathom Pharmaceuticals Inc108.80m-202.94m714.76m427.00714.76m427.00
Jeena Sikho Lifecare Ltd50.67m12.59m721.21m3.76k721.21m3.76k
Cronos Group Inc97.82m26.68m722.06m626.00722.06m626.00
CStone Pharmaceuticals21.56m-40.14m723.22m93.00723.22m93.00
Allergy Therapeutics plc55.04m-40.13m730.83m584.00730.83m584.00
Theravance Biopharma Inc59.38m21.69m733.39m97.00733.39m97.00
Viyash Scientific Ltd135.69m3.42m745.94m1.24k745.94m1.24k
Shanghai Fudan-Zhangjiang Bio-Pharm. Co75.82m-6.68m747.33m925.00747.33m925.00
Tchaikapharma High Quality Medicines AD26.94m2.99m749.49m209.00749.49m209.00
Data as of Feb 06 2026. Currency figures normalised to Allergy Therapeutics PLC's reporting currency: UK Pound GBX

Institutional shareholders

2.84%Per cent of shares held by top holders
HolderShares% Held
JPMorgan Chase Bank, NA (Investment Management)as of 01 Dec 2025129.00m2.10%
West Yorkshire Pension Fundas of 01 Dec 202513.88m0.23%
IG Markets Ltd.as of 01 Dec 20258.20m0.13%
Hargreaves Lansdown Fund Managers Ltd.as of 01 Dec 20256.91m0.11%
Santander Asset Management SA SGIICas of 01 Dec 20254.42m0.07%
HSBC Global Asset Management (UK) Ltd.as of 01 Dec 20253.93m0.06%
Raiffeisen Kapitalanlage-Gesellschaft mbHas of 01 Dec 20252.67m0.04%
Banque Pictet & Cie SAas of 01 Dec 20252.53m0.04%
iDealing.com Ltd.as of 01 Dec 20251.45m0.02%
Bank Julius B�r & Co. AGas of 01 Dec 20251.39m0.02%
More ▼
Data from 31 Mar 2025 - 02 Jan 2026Source: FactSet Research Systems Inc.
Data Provided by LSEG
All markets data located on InvestorsChronicle.co.uk is subject to the Investors Chronicle Terms & Condition
All content on InvestorsChronicle.co.uk is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by IC and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via Investors Chronicle is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. Investors Chronicle is not responsible for any use of content by you outside its scope as stated in the Investors Chronicle Terms & Condition.